Immunovant, Inc. — Director's Dealing 2024

Nov 20, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2024-11-18

Reporting Person: Gloria Melanie (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-18	Common Stock	A	109956	—	Acquired	109956	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-11-18	Stock Option (right to buy)	$25.51	A	137446	Acquired	2034-11-18	Common Stock (137446)	Direct

Footnotes

F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on November 18, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

F2: This option was granted pursuant to the Issuer's 2019 Equity Incentive Plan. The shares underlying the option will vest as to 25% of the shares on November 18, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.